PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal

Stem Cells

Volumn 32, Issue 7, 2014, Pages 1956-1967

  Kobayashi, Michihiro ^a   Bai, Yunpeng ^a   Dong, Yuanshu ^a   Yu, Hao ^a   Chen, Sisi ^a   Gao, Rui ^a   Zhang, Lujuan ^a   Yoder, Mervin C ^a   Kapur, Reuben ^a   Zhang, Zhong Yin ^a   Liu, Yan ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine signaling; Hematopoietic stem cell; KIT; KIT D814V; PRL2; PTP4A2; Self renewal; Stem cell factor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE OF REGENERATING LIVER 2; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 4A2; UNCLASSIFIED DRUG; IMMEDIATE EARLY PROTEIN; PTP4A2 PROTEIN, MOUSE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CELL ONCOGENE; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HYPOPHOSPHATASIA; MOUSE; NONHUMAN; NULL CELL; ONCOGENE C KIT; ONCOGENE SCF; PROTEIN DEPLETION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; 129 MOUSE; ANIMAL; C57BL MOUSE; CELL CULTURE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; IMMEDIATE-EARLY PROTEINS; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; STEM CELL FACTOR;

EID: 84902603173     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1672     Document Type: Article

References (51)

1. Kondo M, Wagers AJ, Manz MG, et al. Biology of hematopoietic stem cells and progenitors: Implications for clinical application. Annu Rev Immunol 2003; 21: 759-806.
2. Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-834.
3. Ding L, Saunders TL, Enikolopov G, et al. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012; 481: 457-462.
4. Lennartsson J, Rönnstrand L,. Stem cell factor receptor/c-Kit: From basic science to clinical implications. Physiol Rev 2012; 92: 1619-1649.
5. Broudy VC,. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345-1364.
6. Lyman SD, Jacobsen SE,. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-1134.
7. Li CL, Johnson GR,. Stem cell factor enhances the survival but not the self-renewal of murine hematopoietic long-term repopulating cells. Blood 1994; 84: 408-414.
8. Keller JR, Ortiz M, Ruscetti FW,. Steel factor (c-kit ligand) promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division. Blood 1995; 86: 1757-1764.
9. Ikuta K, Weissman IL,. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc Natl Acad Sci USA 1992; 89: 1502-1506.
10. Miller CL, Rebel VI, Lemieux ME, et al. Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells. Exp Hematol 1996; 24: 185-194.
11. Sharma Y, Astle CM, Harrison DE,. Heterozygous kit mutants with little or no apparent anemia exhibit large defects in overall hematopoietic stem cell function. Exp Hematol 2007; 35: 214-220.
12. W/W mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity 2002; 17: 277-288.
13. Miller CL, Rebel VI, Helgason CD, et al. Impaired steel factor responsiveness differentially affects the detection and long-term maintenance of fetal liver hematopoietic stem cells in vivo. Blood 1997; 89: 1214-1223.
14. Thorén LA, Liuba K, Bryder D, et al. Kit regulates maintenance of quiescent hematopoietic stem cells. J Immunol 2008; 180: 2045-2053.
15. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
16. Longley BJ, Reguera MJ, Ma Y,. Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001; 25: 571-576.
17. Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726-727.
18. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
19. Kitayama H, Kanakura Y, Furitsu T, et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995; 85: 790-798.
20. Piao X, Bernstein A,. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996; 87: 3117-3123.
21. Ma P, Mali RS, Martin H, et al. Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease. Leukemia 2012; 26: 1499-1506.
22. Mali RS, Ma P, Zeng LF, et al. Role of SHP2 phosphatase in KIT-induced transformation: Identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood 2012; 120: 2669-2678.
23. Diamond RH, Cressman DE, Laz TM, et al. PRL-1, a unique nuclear protein-tyrosine phosphatase, affects cell growth. Mol Cell Biol 1994; 14: 3752-3762.
24. Cates CA, Michael RL, Stayrook KR, et al. Prenylation of oncogenic human PTP (CAAX) protein-tyrosine phosphatases. Cancer Lett 1996; 110: 49-55.
25. Zeng Q, Hong W, Tan YH,. Mouse PRL-2 and PRL-3, two potentially prenylated protein-tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 1998; 244: 421-427.
26. Wang J, Kirby CE, Herbst R,. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem 2002; 277; 46659-46668.
27. 2 as a potential oncogene. Cancer Lett 2002; 175: 63-69.
28. Cip1/Waf1 by PRL tyrosine phosphatases. Cancer Lett 2003; 202: 201-211.
29. Liang F, Liang J, Wang WQ, et al. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 2007; 282: 5413-5419.
30. Stephens BJ, Han H, Gokhale V, et al. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 2005; 4: 1653-1661.
31. Bessette DC, Qiu D, Pallen CJ,. PRL PTPs: Mediators and markers of cancer progression. Cancer Metastasis Rev 2008; 27: 231-252.
32. Dong Y, Zhang L, Zhang S, et al. Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (phosphatase and tensin homologue deleted on chromosome 10) and activating Akt protein. J Biol Chem 2012; 287: 32172-32179.
33. Mohamed AN, Palutke M, Eisenberg L, et al. Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant. Cancer Genet Cytogenet 2001; 126: 45-51.
34. Martinez-Climent JA, Alizadeh AA, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2003; 101: 3109-3117.
35. Yagi T, Morimoto A, Eguchi M, et al. Identification of a gene expression signature associated with pediatric AML prognosis. Blood 2003; 102: 1849-1856.
36. Akiyama S, Dhavan D, Yi T,. PRL-2 increases Epo and IL-3 responses in hematopoietic cells. Blood Cells Mol Dis 2010; 44: 209-214.
37. Liu Y, Elf SE, Miyata Y, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009; 4: 37-48.
38. Kobayashi M, Srour EF,. Regulation of murine hematopoietic stem cell quiescence by Dmtf1. Blood 2011; 118: 6562-6571.
39. Zhao Z, Lee CC, Monckton DG, et al. Characterization and genomic mapping of genes and pseudogenes of a new human protein tyrosine phosphatase. Genomics 1996; 35: 172-181.
40. Dumaual CM, Sandusky GE, Crowell PL, et al. Cellular localization of PRL-1 and PRL-2 gene expression in normal adult human tissues. J Histochem Cytochem 2006; 54: 1401-1412.
41. Semba S, Mizuuchi E, Yokozaki H,. Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma. Cancer Sci 2010; 101: 2254-2261.
42. Song MS, Salmena L, Pandolfi PP,. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283-296.
43. Ito K, Bernardi R, Pandolfi PP,. A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. Curr Opin Genet Dev 2009; 19: 51-59.
44. Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441: 518-522.
45. Alimonti A, Carracedo A, Clohessy JG, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010; 42: 454-458.
46. Garcia-Cao I, Song MS, Hobbs RM, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012; 149: 49-62.
47. Cheng T, Rodrigues N, Shen H, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000; 287: 1804-1808.
48. Zou P, Yoshihara H, Hosokawa K, et al. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell 2011; 9: 247-261.
49. Stiles B, Groszer M, Wang S, et al. PTENless means more. Dev Biol 2004; 273: 175-184.
50. Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-192.
51. Reith AD, Rottapel R, Giddens E, et al. W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. Genes Dev 1990; 4: 390-400.